Physician profile
Philippe A Saxe
NPI 1336240076
$17,549.34
in general payments reported to CMS, 2019-2025
44 companies · $2,665 in 2025
The $2,665 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,755 · 2020: $1,530 · 2021: $2,075 · 2022: $2,153 · 2023: $1,825 · 2024: $4,547 · 2025: $2,665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,802 · Consulting Fee: $2,160 · Travel and Lodging: $74.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,802.19 |
| Consulting Fee | $2,160.00 |
| Travel and Lodging | $74.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,918.95 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Amgen INC. | $2,267.26 | 2019-2025 | Evenity, Krystexxa, Enbrel |
| Abbvie INC. | $1,940.20 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Ucb, INC. | $1,547.66 | 2020-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $1,340.46 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $981.38 | 2019-2025 | Orencia |
| Pfizer INC. | $881.57 | 2019-2025 | |
| Glaxosmithkline, LLC. | $776.61 | 2019-2025 | Benlysta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $690.35 | 2019-2025 | Ofev, Cyltezo, Spevigo |
| Mallinckrodt Hospital Products INC. | $677.35 | 2020-2025 | Acthar |
| Radius Health, INC. | $520.56 | 2019-2025 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $444.96 | 2021-2025 | Saphnelo, Flumist Quadrivalent |
| Genentech USA, INC. | $310.47 | 2019-2025 | Actemra, Gazyva |
| Sobi, INC | $300.03 | 2019-2025 | |
| Genzyme Corporation | $299.08 | 2019-2025 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philippe Saxe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.